Pharma News

Revenue for Fluarix is expected to have a CAGR of 2.12% through 2038

Fluarix is a Inactivated Vaccine owned by GSK, and is involved in 53 clinical trials, which were completed.

Influenza vaccine stimulate the body’s immune system to recognize the agent as foreign and destroy it. It also helps the body’s immune system to ‘remember’ the agent, so that the immune system can easily recognize and destroy any of the microbes that it encounters again in the future. The vaccine candidate works by targeting primarily the induction of neutralizing antibodies directed against the major viral envelope protein, hemagglutinin (HA). Hemagglutinin (HA) is a species specific binding protein that allows for the virus to bind to the cell membrane of host respiratory cells and propagate through cellular processes. This higher antigen content has resulted in substantially improved serum hemagglutination inhibition (HI) antibody responses.

The revenue for Fluarix is expected to reach a total of $21.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Fluarix NPV Report.

Fluarix is currently owned by GSK.

Fluarix Overview

Influenza virus trivalent split-virion vaccine (Fluarix) is an active immunizing preparation propagated in fertilized hens’ eggs from healthy chicken flocks. Fluarix contains A/Michigan/45/2015 (H1N1) pdm09-like virus; A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus. It is formulated as suspension for intramuscular or deep subcutaneous route of administration. Fluarix is indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccine.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020.
The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Fluarix

Report Segments
Drug Name
Administration Pathway
  • Intramuscular
  • Subcutaneous
Therapeutic Areas
Key Companies
Highest Development Stage

Source link
#Revenue #Fluarix #expected #CAGR

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *